Press releaseBusiness Wire
Atara Biotherapeutics
ATRA · NASDAQ
$9.16+$0.20 (+2.23%)TodayMarket closed ·
Prev close $8.96
Latest news
- Press releaseBusiness Wire
Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration
- News
Atara Biotherapeutics Q2 EPS $(0.32), Inline, Sales $630.000K Beat $366.667K Estimate
- Press releaseBusiness Wire
Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress
- Press releaseBusiness Wire
Atara Biotherapeutics Announces Changes to Its Board of Directors
- Press releasePRNewswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA
- Press releaseBusiness Wire
ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
- Press releaseGlobe Newswire
ATRA DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 22 Deadline in Securities Class Action - ATRA
- Press releaseBusiness Wire
ATRA FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026
- Press releaseNewsfile
ATARA DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
- Press releaseGlobe Newswire
ATRARA (NASDAQ:ATRA) DEADLINE MAY 22nd: Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit
- Press releasePRNewswire
ATRA EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026
- Press releaseBusiness Wire
Deadline Soon: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
- Press releasePRNewswire
Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your Rights - ATRA
- Press releasePRNewswire
ATRA UPCOMING DEADLINE : The Gross Law Firm Alerts Atara Biotherapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm
- Press releasePRNewswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit
- Press releaseGlobe Newswire
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit
- Press releasePRNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA
- Press releasePRNewswire
ATRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026
- News
Atara Biotherapeutics Q1 EPS $(0.29) Beats $(0.41) Estimate, Sales $516.000K Miss $2.850M Estimate
- Press releaseBusiness Wire
Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress
- Press releaseGlobe Newswire
Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
- Press releaseGlobe Newswire
Portnoy Law Firm Announces Class Action on Behalf of Atara Biotherapeutics, Inc. Investors
- Press releasePRNewswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releaseBusiness Wire
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel
- Press releaseGlobe Newswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA
- Press releaseGlobe Newswire
Portnoy Law Firm Announces Class Action on Behalf of Atara Biotherapeutics, Inc. Investors
- Press releasePRNewswire
The Gross Law Firm Reminds Atara Biotherapeutics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of May 22, 2026 - ATRA
- Press releasePRNewswire
ATRA SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026
- Press releaseBusiness Wire
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- News
'A Rare Disease Drug Was Approvable, Then It Wasn't. Inside A Surprise Rejection By The FDA; Drugmakers Say Agency's Reasons For Decision Were At Odds With Previous Exchanges' - STAT News
- Newsbiotechanalyzer
Atara's Outlook As Ebvallo Hits Second FDA CRL
- Press releaseBusiness Wire
Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.